{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:24:58Z","timestamp":1772119498679,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s10147-020-01802-x","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T16:02:25Z","timestamp":1602777745000},"page":"355-363","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Second-line chemotherapy using taxane in patients with advanced gastric cancer who presented with severe peritoneal metastasis: a multicenter retrospective study"],"prefix":"10.1007","volume":"26","author":[{"given":"Hiroyuki","family":"Arai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kawahira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Masuishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Muro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako Eguchi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"1802_CR1","unstructured":"International Agency for Research on Cancer. GLOBOCAN 2012: cancer incidence and mortality worldwide. https:\/\/gco.iarc.fr\/. Accessed 22 Sept 2019"},{"key":"1802_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215\u2013221","journal-title":"Lancet Oncol"},{"key":"1802_CR3","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687\u2013697","journal-title":"Lancet"},{"key":"1802_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"6","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Higuchi K, Nishikawa K et al (2015) Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol 6:141\u2013148","journal-title":"Ann Oncol"},{"key":"1802_CR5","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224\u20131235","journal-title":"Lancet Oncol"},{"key":"1802_CR6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s10120-003-0243-6","volume":"6","author":"T Fujimura","year":"2003","unstructured":"Fujimura T, Ishii K, Oyama K et al (2003) A new scoring system for peritoneal metastasis in gastric cancer. Gastric Cancer 6:146\u2013152","journal-title":"Gastric Cancer"},{"key":"1802_CR7","doi-asserted-by":"publisher","first-page":"7478","DOI":"10.3748\/wjg.v22.i33.7478","volume":"22","author":"J Wei","year":"2016","unstructured":"Wei J, Wu ND, Liu BR (2016) Regional but fatal: Intraperitoneal metastasis in gastric cancer. World J Gastroenterol 22:7478\u20137485","journal-title":"World J Gastroenterol"},{"key":"1802_CR8","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/jjco\/hys111","volume":"42","author":"S Iwasa","year":"2012","unstructured":"Iwasa S, Goto M, Yasui H et al (2012) Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake. Jpn J Clin Oncol 42:787\u2013793","journal-title":"Jpn J Clin Oncol"},{"key":"1802_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10120-011-0056-y","volume":"15","author":"S Iwasa","year":"2012","unstructured":"Iwasa S, Nakajima TE, Nakamura K et al (2012) First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer. Gastric Cancer 15:21\u201326","journal-title":"Gastric Cancer"},{"key":"1802_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s10147-017-1198-7","volume":"23","author":"H Hara","year":"2018","unstructured":"Hara H, Kadowaki S, Asayama M et al (2018) First-line bolus 5-fluorouracil plus leucovorin for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intake. Int J Clin Oncol 23:275\u2013280","journal-title":"Int J Clin Oncol"},{"key":"1802_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s10120-012-0143-8","volume":"16","author":"K Shitara","year":"2013","unstructured":"Shitara K, Mizota A, Matsuo K et al (2013) Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis. Gastric Cancer 16:48\u201355","journal-title":"Gastric Cancer"},{"key":"1802_CR12","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S1470-2045(09)70259-1","volume":"10","author":"N Boku","year":"2009","unstructured":"Boku N, Yamamoto S, Fukuda H et al (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10:1063\u20131069","journal-title":"Lancet Oncol"},{"key":"1802_CR13","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1186\/s12885-019-5720-3","volume":"19","author":"H Arai","year":"2019","unstructured":"Arai H, Iwasa S, Boku N et al (2019) Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study. BMC Cancer 19:652","journal-title":"BMC Cancer"},{"key":"1802_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-020-01043-x","author":"TE Nakajima","year":"2020","unstructured":"Nakajima TE, Yamaguchi K, Boku N et al (2020) Randomized phase II\/III study of 5-fluorouracil\/l-leucovorin versus 5-fluorouracil\/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108\/WJOG7312G). Gastric Cancer. https:\/\/doi.org\/10.1007\/s10120-020-01043-x","journal-title":"Gastric Cancer"},{"key":"1802_CR15","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00280-018-3569-9","volume":"81","author":"S Iizumi","year":"2018","unstructured":"Iizumi S, Takashima A, Sakamaki K et al (2018) Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis. Cancer Chemother Pharmacol 81:981\u2013989","journal-title":"Cancer Chemother Pharmacol"},{"key":"1802_CR16","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1007\/s10120-015-0542-8","volume":"19","author":"T Nishina","year":"2016","unstructured":"Nishina T, Boku N, Gotoh M et al (2016) Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407). Gastric Cancer 19:902\u2013910","journal-title":"Gastric Cancer"},{"key":"1802_CR17","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","volume":"31","author":"S Hironaka","year":"2013","unstructured":"Hironaka S, Ueda S, Yasui H et al (2013) Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 31:4438\u20134444","journal-title":"J Clin Oncol"},{"key":"1802_CR18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S2468-1253(16)30219-9","volume":"2","author":"K Shitara","year":"2017","unstructured":"Shitara K, Takashima A, Fujitani K et al (2017) Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol 2:277\u2013287","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1802_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","volume":"15","author":"HE Ford","year":"2014","unstructured":"Ford HE, Marshall A, Bridgewater JA et al (2014) Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 15:78\u201386","journal-title":"Lancet Oncol"},{"key":"1802_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31\u201339","journal-title":"Lancet"},{"key":"1802_CR21","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1200\/JCO.2011.39.4585","volume":"30","author":"JH Kang","year":"2012","unstructured":"Kang JH, Lee SI, Lim DH et al (2012) Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30:1513\u20131518","journal-title":"J Clin Oncol"},{"key":"1802_CR22","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1016\/j.ejca.2011.06.002","volume":"47","author":"PC Thuss-Patience","year":"2011","unstructured":"Thuss-Patience PC, Kretzschmar A, Bichev D et al (2011) Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer\u2013a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 47:2306\u20132314","journal-title":"Eur J Cancer"},{"key":"1802_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12885-018-4057-7","volume":"18","author":"H Matsumoto","year":"2018","unstructured":"Matsumoto H, Kawazoe A, Shimada K et al (2018) A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites. BMC Cancer 18:120","journal-title":"BMC Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01802-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-020-01802-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01802-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T01:42:11Z","timestamp":1634262131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-020-01802-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1802"],"URL":"https:\/\/doi.org\/10.1007\/s10147-020-01802-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.12810\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"assertion":[{"value":"31 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"TM reports honoraria from Taiho, Lilly Japan, Yakult Honsha, and Sanofi. KM reports honoraria from Bristol Myers-Squibb, Taiho, and Eli Lilly, and research funding from Bristol Myers Squibb and Taiho. TEN reports honoraria from Bristol Myers-Squibb, Sawai, Nippon Kayaku, Yakult, Taiho, and Eli Lilly, and research funding Nippon Kayaku, Yakult, Taiho, and Eli Lilly. None of the remaining authors have potential conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}